Description
The Semaglutide 12mg Pen is a single disposable, prefilled pen containing 12 mg of semaglutide in total.
Pricing
- 1 to 4 pens: $400 each
- 5 to 9 pens: $300 each
- 10 or more pens: $200 each
Ordering
A valid prescription is required. Every order is reviewed by our partner pharmacy before it is dispatched, and you will receive an email once it is approved. Payment is by cryptocurrency or cash on delivery.
Use only as directed by your prescribing doctor.
Clinical trial results: semaglutide
Published phase 3 trials studied semaglutide 2.4 mg once weekly (marketed as Wegovy) alongside diet and physical activity. The strength sold on this page (12 mg pen) is not the presentation used in these trials.
| Trial | Population (n) | Dose / duration | Main result vs placebo | Source |
|---|---|---|---|---|
| STEP 1 (NEJM 2021) | Adults with obesity/overweight, no diabetes (n=1,961) | 2.4 mg weekly, 68 weeks | −14.9% vs −2.4% placebo | Wilding et al., DOI 10.1056/NEJMoa2032183 |
| STEP 2 (Lancet 2021) | Adults with overweight/obesity and type 2 diabetes (n=1,210) | 2.4 mg weekly, 68 weeks | −9.6% vs −3.4% placebo | Davies et al., DOI 10.1016/S0140-6736(21)00213-0 |
| SELECT (NEJM 2023) | Adults with overweight/obesity and established cardiovascular disease, no diabetes (n=17,604) | 2.4 mg weekly, mean follow-up 39.8 months | Major adverse cardiovascular events: 6.5% vs 8.0% placebo (hazard ratio 0.80) | Lincoff et al., DOI 10.1056/NEJMoa2307563 |
Common side effects reported in trials
- STEP 1: nausea 44.2% vs 17.4% placebo; diarrhoea 31.5% vs 15.9%; vomiting 24.8% vs 6.6%; constipation 23.4% vs 9.5%.
- STEP 1: 7.0% stopped treatment because of adverse events vs 3.1% on placebo.
- The FDA label carries a boxed warning about thyroid C-cell tumours and lists pancreatitis and gallbladder disease among warnings: Wegovy prescribing information (DailyMed).
Individual results differ and results vary. Figures above are group averages from the cited studies, not a prediction for any individual. This summary is for information only and is not medical advice; speak to a licensed healthcare professional.
Frequently asked questions
What dose of semaglutide was studied for weight management?
The STEP trials studied 2.4 mg once weekly, reached by gradual dose escalation, alongside diet and physical activity (Wilding et al., NEJM 2021).
What average weight change was seen in STEP 1?
Over 68 weeks the mean change in body weight was −14.9% with semaglutide 2.4 mg vs −2.4% with placebo. Individual results differed.
What were the most common side effects?
Gastrointestinal effects. In STEP 1, nausea was reported by 44.2% on semaglutide vs 17.4% on placebo, and diarrhoea by 31.5% vs 15.9%.
Reviews
There are no reviews yet.